Loading
GH
Guardion Health Sciences, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Radoff Bradley Louis, was filed 11 Jan 2023.
Guardion Health Sciences, Inc.: what insiders have been doing
Guardion Health Sciences, Inc., classified in the Healthcare & Pharma sector, is a listed company. Its insiders report their share dealings to SEC (Form 4). Nothing new has been filed by managers of Guardion Health Sciences, Inc. in twelve months, the latest record being from 28 August 2024.
Over the whole record (from 2017), the tally stands at 8 purchases and 4 sales.
Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
45
Thresholds
n/a
Buy Volume
€1M
8 ops. · all time
Sell Volume
€1M
4 ops. · all time
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2023FY ended December 2023 · cache
Income statement
RevenueUS$10.5M
Gross profitUS$4.6M44% margin
Net incomeUS$136.1k1.3% margin
Last declaration on 28 August 2024
Declarations45 total
44,550 shares@ US$14.4625.9% of flowCommon StockSEC:0000921895-24-001969:1
8,250 shares@ US$15.775.2% of flowCommon StockSEC:0000921895-24-001969:2
10,054 shares@ US$13.79895.6% of flowCommon StockSEC:0000921895-24-001969:3
52,686 shares@ US$13.540461.1% of flowCommon StockSEC:0000921895-24-001969:0
20,838 shares@ US$7.19486.3% of flowCommon StockSEC:0000921895-23-000097:1
Canonical exit: 9 Apr 2023 (T+90)
18,630 shares@ US$7.31125.7% of flowCommon StockSEC:0000921895-23-000097:2
Canonical exit: 10 Apr 2023 (T+90)
13,270 shares@ US$7.99894.4% of flowCommon StockSEC:0000921895-23-000097:3
Canonical exit: 10 Apr 2023 (T+90)
63,983 shares@ US$6.776238.9% of flowCommon StockSEC:0000921895-23-000097:0
Canonical exit: 9 Apr 2023 (T+90)
37,175 shares@ US$0.6581.7% of flowCommon StockSEC:0001493152-22-016968:0
152,671 sharesCommon StockSEC:0001493152-22-005971:0
5,500 shares@ US$1.2318.0% of flowCommon stockSEC:0001493152-21-021791:1
Canonical exit: 29 Nov 2021 (T+90)
4,500 shares@ US$1.256818.3% of flowCommon stockSEC:0001493152-21-021791:0
Canonical exit: 28 Nov 2021 (T+90)
5,000 shares@ US$1.25100.0% of flowCommon stockSEC:0001493152-21-021686:0
Canonical exit: 28 Nov 2021 (T+90)
10,000 shares@ US$1.14100.0% of flowCommon Stock, $0.001 par valueSEC:0001493152-21-020894:0
916,023 shares0Common StockSEC:0001493152-21-000384:0
2,000 shares@ US$0.3321.9% of flowCommon StockSEC:0001717370-19-000002:0
20,000 sharesCommon StockSEC:0001493152-19-013279:1
20,000 shares@ US$0.4425.1% of flowCommon StockSEC:0001493152-19-013279:0
1,250 shares@ US$4.0042.2% of flowCommon StockSEC:0001144204-19-020086:0
250 shares@ US$3.557.5% of flowCommon StockSEC:0001144204-19-020086:1
300 shares@ US$3.53100.0% of flowCommon StockSEC:0001144204-19-019063:0
1,000 shares@ US$4.00100.0% of flowCommon StockSEC:0001144204-19-019054:0
6,500 shares@ US$4.0073.0% of flowCommon StockSEC:0001144204-19-019060:0
2,500 shares@ US$4.0047.6% of flowCommon StockSEC:0001144204-19-019058:0
2,742,000 shares0Common StockSEC:0001717370-18-000001:0
25 of 45 declarations
About Guardion Health Sciences, Inc.
Guardion Health Sciences, Inc. is a U.S.-listed company on the Nasdaq Stock Market LLC under the ticker GHSI. The company is incorporated in the United States and has historically referenced Houston, Texas, as its operational headquarters, while its early manufacturing and product-development footprint was tied to California, including the San Diego/Irvine area. Guardion was formed in December 2009 as P4L Health Sciences, LLC and later converted into a Delaware corporation in 2015, reflecting a typical evolution from private operating entity to public-market issuer.
Guardion’s business is centered on clinical nutrition and ocular health. The company has positioned itself as a specialty health sciences platform focused on science-based, clinically supported products for consumer eye health. Its current commercial emphasis includes Lumega-Z and GlaucoCetin, both marketed as ocular-health nutrition products. Lumega-Z was reformulated and relaunched in March 2024 as a drink-mix powder at a lower retail price than the prior liquid formulation, a move designed to improve accessibility, support existing customers, and broaden the addressable consumer base. Guardion sells these products through its own digital channels and addresses consumers, healthcare professionals, providers, and their patients.
Read moreShow less
Over time, the company has also built out a broader ophthalmic and diagnostic-related heritage. Earlier product development included MapcatSF, a device designed to measure macular pigment optical density. In 2017, Guardion acquired substantially all of the assets of VectorVision, a business focused on standardization tools for contrast sensitivity, glare sensitivity, low-contrast acuity, and ETDRS visual acuity testing. That history suggests the company has tried to combine nutrition-based products with diagnostic and measurement capabilities, although the current commercial profile appears much narrower than in prior years.
From a competitive standpoint, Guardion operates in a niche market where clinical credibility, brand trust, and product differentiation matter more than scale. It is small relative to large nutrition, consumer-health, or ophthalmology companies, but it can potentially benefit from specialization in eye health and from products that are marketed as science-backed and clinically supported. The trade-off is clear: the company’s narrow product set and limited scale create dependence on a small number of offerings and heighten execution risk.
Recent developments have been material. In 2024, Guardion announced the reformulation and relaunch of Lumega-Z. The company also disclosed a proposed sale of the Viactiv brand and business and a plan of liquidation and dissolution, signaling a major strategic reset and possible wind-down of legacy operations. Quarterly filings in 2024 showed modest revenues and underscore the company’s micro-cap profile. For investors following U.S. insider activity and SEC Form 4 filings, Guardion Health Sciences remains a highly specialized, small-cap healthcare name on Nasdaq in the United States, with a story defined by restructuring, niche ocular-health products, and strategic uncertainty.
